CA2667513A1 - A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one - Google Patents

A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one Download PDF

Info

Publication number
CA2667513A1
CA2667513A1 CA002667513A CA2667513A CA2667513A1 CA 2667513 A1 CA2667513 A1 CA 2667513A1 CA 002667513 A CA002667513 A CA 002667513A CA 2667513 A CA2667513 A CA 2667513A CA 2667513 A1 CA2667513 A1 CA 2667513A1
Authority
CA
Canada
Prior art keywords
fumarate
fumarate salt
medicament
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002667513A
Other languages
English (en)
French (fr)
Inventor
Fabio Neggiani
Laura Dini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2667513A1 publication Critical patent/CA2667513A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002667513A 2006-11-02 2007-10-31 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one Abandoned CA2667513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002102A ITMI20062102A1 (it) 2006-11-02 2006-11-02 Nuovui sali di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidrobenzo-d-isossazol-4-one
ITMI2006A002102 2006-11-02
PCT/IB2007/003291 WO2008053325A1 (en) 2006-11-02 2007-10-31 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one

Publications (1)

Publication Number Publication Date
CA2667513A1 true CA2667513A1 (en) 2008-05-08

Family

ID=39145485

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002667513A Abandoned CA2667513A1 (en) 2006-11-02 2007-10-31 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
CA002667515A Abandoned CA2667515A1 (en) 2006-11-02 2007-10-31 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002667515A Abandoned CA2667515A1 (en) 2006-11-02 2007-10-31 A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one

Country Status (20)

Country Link
US (2) US20100069451A1 (OSRAM)
EP (2) EP2094674B1 (OSRAM)
JP (2) JP2010509309A (OSRAM)
KR (2) KR20090082452A (OSRAM)
CN (2) CN101535282A (OSRAM)
AT (2) ATE504578T1 (OSRAM)
AU (2) AU2007315833A1 (OSRAM)
BR (2) BRPI0718392A2 (OSRAM)
CA (2) CA2667513A1 (OSRAM)
DE (2) DE602007013801D1 (OSRAM)
HR (2) HRP20090477A2 (OSRAM)
IL (2) IL198444A0 (OSRAM)
IT (1) ITMI20062102A1 (OSRAM)
MX (2) MX2009004293A (OSRAM)
NO (2) NO20092115L (OSRAM)
NZ (2) NZ577311A (OSRAM)
RS (2) RS20090388A (OSRAM)
RU (2) RU2009120724A (OSRAM)
WO (2) WO2008053325A1 (OSRAM)
ZA (2) ZA200903618B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
EP2112142A1 (en) * 2008-04-24 2009-10-28 Abiogen Pharma S.p.A. Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
WO2011010332A1 (en) * 2009-07-23 2011-01-27 Abiogen Pharma S.P.A. Process for preparing rel-(3r*,3as*,7as*)-3-benzyl-2-methyl-2,3, 3a,4,5,6,7,7a- octahydrobenzo[d]isoxazoi-4-one or a salt thereof
WO2016123275A1 (en) * 2015-01-30 2016-08-04 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161595A (en) * 1978-10-02 1979-07-17 Bristol-Myers Company Levulinic acid salt
US4419358A (en) * 1981-11-12 1983-12-06 Mead Johnson & Company Isethionic acid salt of 9-cyclohexyl-2-propoxy-9H-purine-6-amine and compositions containing an effective bronchodilating concentration of it
GB2264299B (en) * 1992-02-19 1995-07-26 British Tech Group Iso-oxazolidine derivatives

Also Published As

Publication number Publication date
NO20092114L (no) 2009-05-29
CN101535282A (zh) 2009-09-16
US20100069451A1 (en) 2010-03-18
HRP20090477A2 (hr) 2009-11-30
DE602007013801D1 (de) 2011-05-19
MX2009004293A (es) 2009-05-08
CN101535281A (zh) 2009-09-16
EP2094674B1 (en) 2011-03-16
WO2008053326A1 (en) 2008-05-08
NO20092115L (no) 2009-05-29
WO2008053325A1 (en) 2008-05-08
RS20090388A (sr) 2010-12-31
ITMI20062102A1 (it) 2008-05-03
JP2010509310A (ja) 2010-03-25
KR20090082452A (ko) 2009-07-30
IL198443A0 (en) 2010-02-17
ZA200903618B (en) 2010-07-28
BRPI0718391A2 (pt) 2013-11-26
AU2007315832A1 (en) 2008-05-08
ATE504578T1 (de) 2011-04-15
NZ577311A (en) 2010-10-29
RS20090389A (sr) 2010-12-31
RU2009120667A (ru) 2010-12-10
US20100069450A1 (en) 2010-03-18
DE602007013278D1 (de) 2011-04-28
MX2009004294A (es) 2009-05-08
CA2667515A1 (en) 2008-05-08
ZA200903810B (en) 2010-07-28
EP2094675A1 (en) 2009-09-02
ATE502021T1 (de) 2011-04-15
HRP20090470A2 (hr) 2009-11-30
RU2009120724A (ru) 2010-12-10
BRPI0718392A2 (pt) 2013-11-26
NZ577978A (en) 2010-10-29
EP2094674A1 (en) 2009-09-02
JP2010509309A (ja) 2010-03-25
KR20090077014A (ko) 2009-07-13
AU2007315833A1 (en) 2008-05-08
EP2094675B1 (en) 2011-04-06
IL198444A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
LU82386A1 (fr) Amides d'acyl-carnitines,leur procede de preparation et compositions pharmaceutiques contenant ces amides
EP0506532A1 (fr) Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant
CH639653A5 (fr) Aminothiazoles et composition pharmaceutique les contenant.
CH644348A5 (fr) Amino-ethers oxydes, leur procede de preparation et medicament les contenant.
US11179386B2 (en) Analogs of deutetrabenazine, their preparation and use
US20090005457A1 (en) Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereof
WO2001092261A1 (fr) Derives de 1,4-diazabicyclo [3.2.2]nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
EP0446141B1 (fr) Nouveaux dérivés d'imidazo [1,2-C] quinazoline leur procédé de préparation et les compositions pharmaceutiques les renfermant
EP2094674B1 (en) A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
FR2776660A1 (fr) Diazepino-indoles de phosphodiesterases iv
WO2003044024A1 (fr) Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
CA1228359A (fr) Procede de preparation de nouveaux derives de la quinoleine
EP2271343A1 (fr) Sels de quinoleines 2-substituees
NL8603236A (nl) Optisch actieve 2-chloor-12-(3-dimethylamino-2-methyl-propyl)-12h-dibenzod,g1,3,6dioxazocinen en een werkwijze voor de bereiding ervan.
JPH0341459B2 (OSRAM)
KR20030027119A (ko) 1,3,4-옥사디아졸 유도체의 신규 결정, 그 제조 방법 및그것을 유효 성분으로서 함유하는 약제
JP2009520813A (ja) カルバメート系抗生物質
EP3359538B9 (fr) Derivés de 1,4,8-triazaphénanthrène pour le traitement de maladies neurodégénératives
FR2517679A1 (fr) Derives de diaza-3,7a cyclohepta (j,k) fluorenes, leur preparation et leur application en therapeutique
BE897281A (fr) Le 2 (hexahydroazepine)-n-(2,6-dimethylphenyle)-acetamide son derive chlorhydrate, procede pour leur obtention et compositions pharmaceutique les contenant
EP0066934A1 (fr) Sels de nitrofurantoine, leur préparation et leur utilisation
BE878563A (fr) Nouvelles alpha-alkyl-o-oxybenzylamines, leur preparation et leur application comme medicaments

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20121031